GSK’s MenABCWY vaccine combines the antigenic components of the Company’s two well-established meningococcal vaccines—BEXSERO (Meningococcal Group B Vaccine) and MENVEO (Meningococcal ...

GSK said a Centers for Disease Control and Prevention advisory board called for its drug Penmenvy to be part of the adolescent meningococcal vaccination schedule. Penmenvy was recommended to help ...

GSK said its five-in-one meningococcal vaccine Penmenvy was approved by the U.S. Food and Drug Administration. The British pharmaceutical company on Monday said the vaccine was authorized for use ...

GSK’s 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, is currently under review in the United States. A decision from the FDA is expected on Feb. 14, 2025.

GSK has received the Food and Drug Administration’s permission for Penmenvy (meningococcal groups A, B, C, W and Y vaccine) for use in individuals aged 10 through 25 years.

Importantly, Penmenvy integrates the antigenic components of GSK’s two widely used meningococcal vaccines, Bexsero (Meningococcal Group B Vaccine) and Menveo (Meningococcal [Groups A, C, Y, and ...

The U.S. Food and Drug Administration approved a GSK meningococcal vaccine for people aged 10 to 25, which will be one of its major product launches this year and rival a first-to-market shot from ...

The vaccine combines the antigenic components of GSK’s two well-established meningococcal vaccines, BEXSERO (Meningococcal Group B Vaccine) and MENVEO (Meningococcal [Groups A, C, Y, and W-135 ...

GSK's 5-In-1 Meningococcal Vaccine Gets Positive Recommendation From U.S. Advisory Committee on Immunization Practices Published: April 17, 2025, 2:28 a.m. ET Share Resize ...